PEPGEN INC. Increase (Decrease) in Other Receivables
PEPGEN INC. (PEPG) reported Increase (Decrease) in Other Receivables of -$26.00 thousand for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2024-03-29
- PEPGEN INC. increase (decrease) in other receivables for the quarter ending 2023-12-31 was -$1.00K.
- PEPGEN INC. increase (decrease) in other receivables for the quarter ending 2022-12-31 was -$4.15M, a 640.49% decline year-over-year.
- PEPGEN INC. increase (decrease) in other receivables for the quarter ending 2022-09-30 was -$6.00K, a 100.19% decline year-over-year.
- PEPGEN INC. increase (decrease) in other receivables for the quarter ending 2022-06-30 was -$5.00K, a 101.13% decline year-over-year.
- PEPGEN INC. increase (decrease) in other receivables for fiscal 2023 was -$26.00K.
- PEPGEN INC. increase (decrease) in other receivables for fiscal 2022 was -$4.18M, a 196.34% decline from fiscal 2021.
- PEPGEN INC. increase (decrease) in other receivables for fiscal 2021 was $4.34M.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$26.00K 10-K/A · filed 2024-03-29 | ||
| 2023-09-30 | -$25.00K 10-Q · filed 2023-11-08 | |||
| 2022-12-31 | -$4.15M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$4.16M derived: sum of 2 quarters · filed 2024-03-29 | -$4.16M derived: sum of 3 quarters · filed 2024-03-29 | -$4.18M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$11.00K derived: sum of 2 quarters · filed 2023-11-08 | -$32.00K 10-Q · filed 2023-11-08 | $736.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$26.00K 10-Q · filed 2023-08-08 | $742.00K derived: sum of 3 quarters · filed 2023-08-08 | $3.95M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$21.00K 10-Q · filed 2023-05-11 | $747.00K derived: sum of 2 quarters · filed 2023-05-11 | $3.96M derived: sum of 3 quarters · filed 2023-05-11 | $4.40M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $768.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $3.98M derived: sum of 2 quarters · filed 2023-03-23 | $4.42M derived: sum of 3 quarters · filed 2023-03-23 | $4.34M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.65M derived: sum of 2 quarters · filed 2022-11-10 | $3.57M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $366.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$77.00K 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |